We span integrated therapy from bed to bench and back to the bed. Our focus is finding therapeutic solutions for patients with unmet medical needs. We operate as a program-specific investment fund with a dedicated development platform poised at the cutting edge of French and German development know-how.


We are at a transformational time in biomedical research. Disruptive technologies have made human disease models a reality. Patient-derived material lies at the heart of this effort, which we at Ksilink access through our clinical programs. The models we are creating recapitulate the actual disease mechanisms in patients. Drug development, has been vertically accelerated as a result. Costs are lessened and chances of success bolstered. During this paradigm shift access to patient material and modeling know how is becoming a competitive game changer. Ksilink is designed to be at the forefront of this new development.


Translational Capabilities

Financial De-risking

Scientific De-risking


Connecting Meaningful Endpoints

Integrated Approach


We're a small, talented and passionate team of professionals.

  • Ulf Nehrbass

    Chief Executive Officer

    A graduate of Cambridge University Ulf worked at the Rockefeller University, N.Y.C. and as Section Head of the Institut Pasteur, Paris, before moving into drug development as founder and CEO of Institut Pasteur Korea as well as QurlentTherapeutics.

    • Yong-Jun Kwon

      High Content Screening and Technology Development

      PhD in Functional Genomics from Yonsei University, Seoul, Korea. 11 years of experience in translational research at the Institut Pasteur Korea and the Samsung Medical Center.  He is responsible for Ksilink’s high-content screening and technology development.

      • Mona Boyé

        Scouting and Program Manager

        Mona studied immunobiology in Constance, Germany and obtained her PhD degree in molecular biology from Cardiff Bioschool, UK.  After her postdoc she absolved a training about Intellectual Property at the TH Berlin, Germany.  

        • Antoine de Lacombe

          Chief Financial Officer

          Graduated from Université Paris-Dauphine in management and Institut d’Etudes Politiques de Paris in corporate finance. Antoine started with Ernst & Young Audit.  He then joined a privately-owned Investment fund where he gained experience in corporate finance and restructuring.

          • Peter Sommer

            R&D Portfolio Management and Competitive Intelligence

            PhD in Virology from the University of the Saarland. Peter has gathered 15 years of experience in translational research in Pasteur Institutes in Europe and Asia.

            • François Kien

              Administrative Coordinator

              PhD in Virology from the University of Strasbourg. François spent 9 years in the International Network of Institut Pasteur as scientist and PR officer.


              An integrated bed to bench to bed effort goes far beyond the capacities of a single player. It requires a concerted effort by many sectors of the biomedical enterprise in France and Germany. Ksilink has secured partners across a wide spectrum from both the private and public sectors. They stand for experience
and excellence. Each has made groundbreaking therapeutic innovations. Together, Ksilink and partners span the full range of development competence, and effectively link patient needs to scientific excellence and back again, in a bed–to-bench-to-bed cycle that is truly unique.

              In the new era of ‘next-generation drug development’ with its patient-based disease models, our network of partners across France and Germany is a critical asset. It allows Ksilink’s clients to be first when it comes to accessing academic and clinical development opportunities, and the most ready to implement concrete solutions.



              Ksilink, University of Bonn and Life & Brain

              Read more

              Mr Jean-Yves Le Déaut visits Ksilink

              Read more

              Ksilink and Anagenesis Biotechnologies

              Read more

              Mr Thierry Mandon visits Ksilink

              Read more

              Mrs Michèle Alliot-Marie visits Ksilink

              Read more

              Ksilink and Sanofi

              Read more


              Read more

              Contact Us

              Send Message

              • Our office address

                16 rue d’Ankara, 67000 Strasbourg, France

              • Write us at


              • Visit us at